skip navigation

Skip Nav

HIV/AIDS Clinical Trials

Clinical Trial Search Results

48 studies were found about ( rilpivirine OR Edurant )

TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.

Condition: HIV Infections; HIV-1; Human Immunodeficiency Virus Type 1

NCT ID: NCT00540449

A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir/Ritonavir, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women

Condition: HIV; HIV Infections; Pregnancy

NCT ID: NCT00855335

TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors

Condition: HIV Infections; HIV-1

NCT ID: NCT00543725

A Study on the Safety and Effectiveness of Rilpivirine Hydrochloride (Edurant) Among Adult Filipino Patients With Human Immunodeficiency Virus Type-I Infection

Condition: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

NCT ID: NCT01692470

Study in Healthy Volunteers of the Safety and Metabolism of Different Doses of the Anti-HIV Drug TMC278LA.

Condition: HIV Infection

NCT ID: NCT01275443

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT01641809

A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1

Condition: HIV-1 Infection

NCT ID: NCT01266902

DRV/r + RPV QD: Efficacy and Toxicity Reduction

Condition: HIV-positive Subjects With HIV-RNA <50 Copies/mL

NCT ID: NCT01792570

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of TMC278 in Human Immunodeficiency Virus Infected Adolescents

Condition: Human Immuno Deficiency (HIV) Infections

NCT ID: NCT00799864

A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment

Condition: Human Immunodeficiency Virus-type 1 Infection

NCT ID: NCT01709084

Safety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of Age

Condition: HIV Infections

NCT ID: NCT01975012

Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Condition: HIV-1 Infection

NCT ID: NCT01309243

Pre-Exposure Prophylaxis Using TMC278LA

Condition: HIV Infections

NCT ID: NCT01049932

A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

Condition: Human Immunodeficiency Virus Type 1

NCT ID: NCT00110305

Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR

Condition: HIV-1 Infection

NCT ID: NCT01286740

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

Condition: HIV-1 Infection

NCT ID: NCT01252940

Dolutegravir + Rilpivirine Switch Study (DORISS)

Condition: HIV Infection; HAART-treated; Virologically Controlled

NCT ID: NCT02069834

Safety, Tolerability,and Adherence to Co-formulated Tenofovir-emtricitabine-rilpivirine Used as HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men.

Condition: HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men

NCT ID: NCT01715636

TMC278-TiDP15-C158 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of a Single Dose or Three Successive Doses of Intramuscularly (IM) Injected Long Acting Formulation of TMC278

Condition: HIV Infections

NCT ID: NCT01031589

TMC278-TiDP6-C154: Evaluation of the Possible Influence of Omeprazole Intake - and the pH Increase in the Stomach Triggered by Omeprazole Intake - on the Blood Levels of TMC278 in Healthy Volunteers

Condition: HIV Infections

NCT ID: NCT01001247

TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and Raltegravir

Condition: HIV Infections

NCT ID: NCT01288755

Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir

Condition: HIV

NCT ID: NCT02104700

Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects

Condition: Impaired Cognition; Depression/Anxiety; Poor Quality Sleep; Quality of Life; HIV-1 Infection

NCT ID: NCT02042001

FTC/RPV/TDF on T-Cell Activation, CD4 Cell Count, Inflammatory Biomarkers and Viral Reservoir

Condition: HIV-1 Infection

NCT ID: NCT01777997

A Phase IV, Open-label Single-arm Study Investigating the Pharmacokinetics and Pharmacodynamics of the Antiretroviral Combination of Rilpivirine and Ritonavirboosted Darunavir in Therapy-naive HIV-1 Infected Patients.

Condition: HIV

NCT ID: NCT01736761

The Rilpivirine Cerebrospinal-fluid (CSF) Study

Condition: HIV

NCT ID: NCT01562886

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT01593046

A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects

Condition: Infections, Human Immunodeficiency Virus and Hepatitis

NCT ID: NCT01467531

TMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir.

Condition: Hepatitis C; HIV

NCT ID: NCT01336829

TMC278-TiDP6-C130: Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately Impaired Hepatic Function.

Condition: HIV; AIDS; Hepatic Impairment

NCT ID: NCT00736905

TMC278-TiDP15-C150: Trial to Examine Safety, Tolerability and Plasma Pharmacokinetics of Multiple Doses of TMC278LA.

Condition: HIV-1

NCT ID: NCT00741741

TMC278-TiDP38-C145: A Bioavailability Study in Healthy Adult Volunteers to Evaluate 3 Pediatric Formulations of TMC278 (a Solution, a Suspension, and Granules) Compared to an Adult Tablet Formulation

Condition: Pharmacokinetics; Bioavailability; HIV-1

NCT ID: NCT00812292

Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera

Condition: HIV-1 Infection

NCT ID: NCT01701895

A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Volunteers

Condition: HIV

NCT ID: NCT01268839

TMC278-TiDP6-C121: Drug-drug Interaction Trial to Investigate the Potential Interaction Between TMC278 25 mg Daily and Methadone, at Steady State.

Condition: HIV

NCT ID: NCT00744770

TMC278-TiDP6-C136: Effect of TMC278 on Ethinylestradiol and Norethindrone in Healthy Women.

Condition: HIV; AIDS; Oral Contraceptive

NCT ID: NCT00739622

A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine

Condition: HIV

NCT ID: NCT01701882

Pharmacokinetics of Tenofovir and Tenofovir-diphosphate, Emtricitabine and Emtricitabine-triphosphate, and Rilpivirine Once Daily Over 14 Days Following Drug Intake Cessation in Healthy Volunteers

Condition: HIV

NCT ID: NCT01796431

A Study to Evaluate Safety, Acceptability, Pharmacokinetics, and ex Vivo Pharmacodynamics of TMC278 Long Acting Formulation in HIV-1 Seronegative Participants

Condition: Healthy

NCT ID: NCT01656018

Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients

Condition: Acquired Immunodeficiency Syndrome; HIV Infections

NCT ID: NCT01495702

Kaletra in Combination With Antiretroviral Agents

Condition: Human Immunodeficiency Virus

NCT ID: NCT01076179

Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress

Condition: Cardiovascular Disease

NCT ID: NCT01585038

Pharmacokinetics, Safety, and Efficacy of Cobicistat-boosted Atazanavir or Cobicistat-boosted Darunavir in HIV-1 Infected, Treatment-Experienced, Virologically Suppressed Pediatric Subjects

Condition: Acquired Immune Deficiency Syndrome (AIDS); HIV Infections

NCT ID: NCT02016924

Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)

Condition: Human Immunodeficiency Virus

NCT ID: NCT01814722

Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions

Condition: Human Immunodeficiency Virus; Hepatitis B, Chronic; Hepatitis C, Chronic

NCT ID: NCT01908660

Telaprevir Open-Label Study in Co-Infected Patients

Condition: Hepatitis C, Chronic

NCT ID: NCT01500616

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Condition: HIV Infections

NCT ID: NCT00042289

A Study to Investigate the Effect of Steady-State TMC278 on the Pharmacokinetics of a Single Dose of Digoxin

Condition: Healthy

NCT ID: NCT01519128